Cargando…

Mesenchymal stromal cell therapy alone does not lead to complete restoration of skin parameters in diabetic foot patients within a 3-year follow-up period

[Image: see text] Introduction: Mesenchymal stromal cells (MSCs) administration is an effective option for the treatment of diabetic foot ulcers (DFUs). However, to date, studies assessing long-term outcomes and evaluating skin parameters after cell-based therapy are lacking. We presented the clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Maksimova, Nadezhda V., Michenko, Anna V., Krasilnikova, Olga A., Klabukov, Ilya D., Gadaev, Igor Yu., Krasheninnikov, Michael E., Belkov, Pavel A., Lyundup, Aleksey V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tabriz University of Medical Sciences (TUOMS Publishing Group) 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783077/
https://www.ncbi.nlm.nih.gov/pubmed/35087716
http://dx.doi.org/10.34172/bi.2021.22167
_version_ 1784638445288685568
author Maksimova, Nadezhda V.
Michenko, Anna V.
Krasilnikova, Olga A.
Klabukov, Ilya D.
Gadaev, Igor Yu.
Krasheninnikov, Michael E.
Belkov, Pavel A.
Lyundup, Aleksey V.
author_facet Maksimova, Nadezhda V.
Michenko, Anna V.
Krasilnikova, Olga A.
Klabukov, Ilya D.
Gadaev, Igor Yu.
Krasheninnikov, Michael E.
Belkov, Pavel A.
Lyundup, Aleksey V.
author_sort Maksimova, Nadezhda V.
collection PubMed
description [Image: see text] Introduction: Mesenchymal stromal cells (MSCs) administration is an effective option for the treatment of diabetic foot ulcers (DFUs). However, to date, studies assessing long-term outcomes and evaluating skin parameters after cell-based therapy are lacking. We presented the clinical outcomes of 3 patients, treated for DFUs with the bone marrow MSCs 3 years earlier. Methods: Ultrasound examination was used to compare collagen density and epidermal thickness in areas of healed ulcers in comparison with non-affected skin used as a control. Ultrasound and dermatoscopy were used to exclude neoplasm formation, to assess scar contracture and wound recurrence. Results: In all patients, no ulcer recurrence was detected, which was lower than the expected 60% rate of re-ulceration in diabetic patients in a 3-year period (OD [odds ratio] = 0.095, P = 0.12). No neoplasm formation, no contracture of hypertrophic scar, and adjacent tissue were registered. Collagen ultrasound density was decreased by 57% (P = 0.053) and epidermal thickness was increased by 72% (P = 0.01) in the area of healed ulcers in all patients. Conclusion: MSCs therapy alone did not result in the complete restoration of the skin parameters within a 3-year period. MSCs may represent important adjuvant to the therapy, however, other novel approaches are required to achieve better results.
format Online
Article
Text
id pubmed-8783077
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Tabriz University of Medical Sciences (TUOMS Publishing Group)
record_format MEDLINE/PubMed
spelling pubmed-87830772022-01-26 Mesenchymal stromal cell therapy alone does not lead to complete restoration of skin parameters in diabetic foot patients within a 3-year follow-up period Maksimova, Nadezhda V. Michenko, Anna V. Krasilnikova, Olga A. Klabukov, Ilya D. Gadaev, Igor Yu. Krasheninnikov, Michael E. Belkov, Pavel A. Lyundup, Aleksey V. Bioimpacts Original Research [Image: see text] Introduction: Mesenchymal stromal cells (MSCs) administration is an effective option for the treatment of diabetic foot ulcers (DFUs). However, to date, studies assessing long-term outcomes and evaluating skin parameters after cell-based therapy are lacking. We presented the clinical outcomes of 3 patients, treated for DFUs with the bone marrow MSCs 3 years earlier. Methods: Ultrasound examination was used to compare collagen density and epidermal thickness in areas of healed ulcers in comparison with non-affected skin used as a control. Ultrasound and dermatoscopy were used to exclude neoplasm formation, to assess scar contracture and wound recurrence. Results: In all patients, no ulcer recurrence was detected, which was lower than the expected 60% rate of re-ulceration in diabetic patients in a 3-year period (OD [odds ratio] = 0.095, P = 0.12). No neoplasm formation, no contracture of hypertrophic scar, and adjacent tissue were registered. Collagen ultrasound density was decreased by 57% (P = 0.053) and epidermal thickness was increased by 72% (P = 0.01) in the area of healed ulcers in all patients. Conclusion: MSCs therapy alone did not result in the complete restoration of the skin parameters within a 3-year period. MSCs may represent important adjuvant to the therapy, however, other novel approaches are required to achieve better results. Tabriz University of Medical Sciences (TUOMS Publishing Group) 2022 2021-09-25 /pmc/articles/PMC8783077/ /pubmed/35087716 http://dx.doi.org/10.34172/bi.2021.22167 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc/4.0/ This work is published by BioImpacts as an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ). Non-commercial uses of the work are permitted, provided the original work is properly cited.
spellingShingle Original Research
Maksimova, Nadezhda V.
Michenko, Anna V.
Krasilnikova, Olga A.
Klabukov, Ilya D.
Gadaev, Igor Yu.
Krasheninnikov, Michael E.
Belkov, Pavel A.
Lyundup, Aleksey V.
Mesenchymal stromal cell therapy alone does not lead to complete restoration of skin parameters in diabetic foot patients within a 3-year follow-up period
title Mesenchymal stromal cell therapy alone does not lead to complete restoration of skin parameters in diabetic foot patients within a 3-year follow-up period
title_full Mesenchymal stromal cell therapy alone does not lead to complete restoration of skin parameters in diabetic foot patients within a 3-year follow-up period
title_fullStr Mesenchymal stromal cell therapy alone does not lead to complete restoration of skin parameters in diabetic foot patients within a 3-year follow-up period
title_full_unstemmed Mesenchymal stromal cell therapy alone does not lead to complete restoration of skin parameters in diabetic foot patients within a 3-year follow-up period
title_short Mesenchymal stromal cell therapy alone does not lead to complete restoration of skin parameters in diabetic foot patients within a 3-year follow-up period
title_sort mesenchymal stromal cell therapy alone does not lead to complete restoration of skin parameters in diabetic foot patients within a 3-year follow-up period
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783077/
https://www.ncbi.nlm.nih.gov/pubmed/35087716
http://dx.doi.org/10.34172/bi.2021.22167
work_keys_str_mv AT maksimovanadezhdav mesenchymalstromalcelltherapyalonedoesnotleadtocompleterestorationofskinparametersindiabeticfootpatientswithina3yearfollowupperiod
AT michenkoannav mesenchymalstromalcelltherapyalonedoesnotleadtocompleterestorationofskinparametersindiabeticfootpatientswithina3yearfollowupperiod
AT krasilnikovaolgaa mesenchymalstromalcelltherapyalonedoesnotleadtocompleterestorationofskinparametersindiabeticfootpatientswithina3yearfollowupperiod
AT klabukovilyad mesenchymalstromalcelltherapyalonedoesnotleadtocompleterestorationofskinparametersindiabeticfootpatientswithina3yearfollowupperiod
AT gadaevigoryu mesenchymalstromalcelltherapyalonedoesnotleadtocompleterestorationofskinparametersindiabeticfootpatientswithina3yearfollowupperiod
AT krasheninnikovmichaele mesenchymalstromalcelltherapyalonedoesnotleadtocompleterestorationofskinparametersindiabeticfootpatientswithina3yearfollowupperiod
AT belkovpavela mesenchymalstromalcelltherapyalonedoesnotleadtocompleterestorationofskinparametersindiabeticfootpatientswithina3yearfollowupperiod
AT lyundupalekseyv mesenchymalstromalcelltherapyalonedoesnotleadtocompleterestorationofskinparametersindiabeticfootpatientswithina3yearfollowupperiod